The reintroduction of nonleukoreduced blood: Would patients and clinicians agree?

Transfusion

Volumn 51, Issue 12, 2011, Pages 2739-2743

  Rosenbaum, Lizabeth ^a,b,c   Tomasulo, Peter ^a,b,c   Lipton, Karen Shoos ^a,b,c   Ness, Paul ^a,b,c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b Blood Systems Incorporated   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOCYTE ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADVERSE OUTCOME; ALLOIMMUNIZATION; BLOOD; BLOOD COMPONENT THERAPY; BLOOD STORAGE; CANCER PATIENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DISEASE SEVERITY; HEALTH CARE QUALITY; HEART SURGERY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPROMISED PATIENT; LEUKAPHERESIS; LEUKEMIA; LEUKOCYTE; MEDICAL DECISION MAKING; NONLEUKOREDUCED BLOOD; ORGAN TRANSPLANTATION; PATIENT REFERRAL; POSTTRANSFUSION PURPURA; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEROCONVERSION;

BLOOD COMPONENT TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; FEMALE; HUMANS; LEUKOCYTES; MALE; PATIENT COMPLIANCE;

EID: 80655149215     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03189.x     Document Type: Review

References (39)

1. Nightingale S, Caplan A,. Summary of 1/25/01 and 1/26/01 meeting of the Advisory Committee on Blood Safety and Availability. Health & Human Services. 2001. [cited 2011 May 6]. Available from: URL
2. Sher GD,. Position paper on leukoreduction of the blood supply. Canadian Blood Services. 1999. [cited 2011 May 6]. Available from: URL
3. Alonso-Echanove J, Sippy BD, Chin AE, Cairns L, Haley R, Epstein JS, Richards MJ, Edelhauser H, Hedberg K, Keuhnert MJ, Jarvis WR, Pearson ML,. Nationwide outbreak of red eye syndrome associated with transfusion of leukocyte-reduced red blood cell units. Infect Control Hosp Epidemiol 2006; 27: 1146-52. (Pubitemid 44807455)
4. Jensen LS, Grunnet N, Hanberg-Sorensen F, Jorgensen J,. Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery. Transfusion 1995; 35: 719-22.
5. Blumberg N, Zhao H, Wang H, Messing S, Heal JM, Lyman GH,. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 2007; 47: 573-81. (Pubitemid 46449617)
6. Balducci L, Benson K, Lyman GH, Sanderson R, Fields K, Ballester OF, Elfenbein GJ,. Cost-effectiveness of white-cell reduction filters in treatment of adult acute myelogenous leukemia. Transfusion 1993; 33: 665-70. (Pubitemid 23237598)
7. Lane TA,. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs. Arch Pathol Lab Med 1994; 118: 392-404. (Pubitemid 24112603)
8. Ness PM, Lipton KS,. Selective transfusion protocols: errors and accidents waiting to happen. Transfusion 2001; 41: 713-5. (Pubitemid 32845015)
9. Yazer MH, Podlosky L, Clarke G, Nahirniak SM,. The effect of prestorage WBC reduction on the rate of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion 2004; 44: 10-5. (Pubitemid 38177130)
10. Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL,. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004; 44: 16-24. (Pubitemid 38177131)
11. King KE, Shirey RS, Thoman SK, Bensen-Kennedy D, Tanz WS, Ness PM,. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004; 44: 25-9. (Pubitemid 38177132)
12. Herbert PC, Fergusson DF, Blajchman MA, Wells GA, Kmetic A, Coyle D, Heddle N, Germain M, Goldman M, Toye B, Schweitzer I, vanWalraven C, Devine D, Sher GD,; for Leukoreduction Study Investigators. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003; 289: 1941-9. (Pubitemid 37430225)
13. Izbicki G, Rudensky B, Na'amad M, Hershko C, Huerta M, Hersch M,. Transfusion-related leukocytosis in critically ill patients. Crit Care Med 2004; 32: 439-42. (Pubitemid 38234124)
14. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N,. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348: 841-5. (Pubitemid 26320898)
15. Van Hilten JA, van de Watering LM, van Bockel JH, van de Velde CJ, Kievit J, Brand R, van den Hout WB, Geelkerken RH, Roumen RM, Wesselink RM, Koopman-van Gemert AW, Koning J, Brand A,; for TACTICS. Effects of transfusion with red cells filtered to remove leucocytes: randomized controlled trial in patients undergoing major surgery. BMJ 2004; 328: 1281-8.
16. Llewelyn CA, Taylor RS, Todd AA, Stevens W, Murphy MF, Williamson LM,. The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery. Transfusion 2004; 44: 489-500. (Pubitemid 38437583)
17. Vamvakas EC,. White-blood-cell-containing allogeneic blood transfusion and postoperative infection or mortality: an updated meta-analysis. Vox Sang 2007; 92: 224-32. (Pubitemid 46365029)
18. Frietsch T, Karger R, Scholer M, Huber D, Bruckner T, Kretschmer V, Schmidt S, Leidinger W, Weiler-Lorentz A,. Leukodepletion of autologous whole blood has no impact on perioperative infection rate and length of hospital stay. Transfusion 2008; 48: 2133-42.
19. Vamvakas EC, Blajchman MA,. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97: 1180-95. (Pubitemid 32183738)
20. Baron JF, Gourdin M, Bertrand M, Mercadier A, Delort J, Kieffer E, Coriat P,. The effect of universal leukodepletion of packed red blood cells on postoperative infections in high-risk patients undergoing abdominal aortic surgery. Anesth Analg 2002; 94: 529-37. (Pubitemid 34177544)
21. Phelan HA, Gonzales RP, Patel HD, Caudill JB, Traylor RK, Yancey LR, Sperry JL, Friese RS, Nakonezny PA,. Prestorage leukoreduction ameliorates the effects of aging on banked blood. J Trauma 2010; 69: 330-7.
22. Cesaire R, Kerob-Bauchet B, Bourdonne O, Maier H, Amar KO, Halbout P, Dehee A, Desire N, Dantin F, Bera O, Lezin A,. Evaluation of HTLV-1 removal by filtration of blood cell components in a routine setting. Transfusion 2004; 44: 42-8. (Pubitemid 38177135)
23. Williamson LM, Stainsby D, Jones H, Love E, Chapman CE, Navarrete C, Lucas G, Beatty C, Casbard A, Cohen H,; on behalf of the Serious Hazards of Transfusion Steering Group. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host-disease. Transfusion 2007; 47: 1455-67. (Pubitemid 47101067)
24. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. NEJM 1997; 337: 1861-9.
25. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, Spinelli JJ, Sutherland HJ, Tsang P, Hogge DE,. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103: 333-9. (Pubitemid 38029957)
26. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W,. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598-603.
27. Laupacis A, Brown J, Costello B, Delage G, Freedman J, Hume H, King S, Kleinman S, Mazzulli T, Wells G,. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion 2001; 41: 560-9. (Pubitemid 32378113)
28. Ronghe MD, Foot AB, Cornish JM, Steward CG, Carrington D, Goulden N, Marks DI, Oakhill A,. The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation. Br J Haematol 2002; 118: 1124-7. (Pubitemid 35025979)
29. Smith D, Lu Q, Goldfinger D, Fernando LP, Ziman A,. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction versus cytomegalovirus-seronegiatve. Vox Sang 2010; 98: 29-36.
30. Fung MK, Rao N, Rice J, Ridenour M, Mook W, Triulzi DJ,. Leukoreduction in the setting of open heart surgery: a prospective cohort-controlled study. Transfusion 2004; 44: 30-5. (Pubitemid 38177133)
31. Bilgin YM, van de Watering LM, Eijsman L, Versteegh MI, Brand R, van Oers MH, Brand A,. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004; 109: 2755-60. (Pubitemid 38744552)
32. Van De Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, Harvey MS, Huysmans HA, Brand A,. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery. A randomized clinical trial. Circulation 1998; 97: 562-8. (Pubitemid 28090685)
33. Blumberg N, Heal JM, Cowles JW, Hicks GL, Risher WH, Samuel PK, Kirkley SA,. Leukocyte-reduced transfusions in cardiac surgery. Am J Clin Pathol 2002; 118: 376-81.
34. Martin J, Krause M, Benk C, Lutter G, Siegenthaler M, Beyersdorf F,. Blood cardioplegia filtration. Perfusion 2003; 18 Suppl 1: 75-80. (Pubitemid 36503932)
35. Pearl JM, Drinkwater DC, Laks H, Stein DG, Capouya ER, Bhuta S,. Leukocyte-depleted reperfusion of transplanted human hearts prevents ultrastructural evidence of reperfusion injury. J Surg Res 1992; 52: 298-308.
36. Sawa Y, Taniguchi K, Kadoba K, Nishimura M, Ichikawa H, Amemiya A, Kuratani T, Matsuda H,. Leukocyte depletion attenuates reperfusion injury in patients with left ventricular hypertrophy. Circulation 1996; 93: 1640-6. (Pubitemid 26131339)
37. Leal-Noval SR, Amaya R, Herruzo A, Hernandez A, Ordonez A, Marin Neibla A, Camacho P,. Effects of a leukocyte depleting arterial line filter on perioperative morbidity in patients undergoing cardiac surgery: a controlled randomized trial. Ann Thorac Surg 2005; 80: 1394-400. (Pubitemid 41354126)
38. Volkova V, Klapper E, Pepkowitz SH, Denton T, Gillaspie G, Goldfinger D,. A case-control study of the impact of WBC reduction on the cost of hospital care for patients undergoing coronary artery bypass graft surgery. Transfusion 2009; 42: 1123-6.
39. Walker F, (ARC), Waxman D, (ABC). FDA ULR Workshop transcript. 2005. [cited 2011 May 6]. Available from: URL